A more active treatment has profound effects on the health status of rheumatoid arthritis (RA) patients: results from a population-based RA register in Malmö, Sweden, 1997–2005
(2010) In Scandinavian Journal of Rheumatology 39(3). p.206-211- Abstract
- Methods: A continuously updated population-based RA register was established in the city of Malmo, southern Sweden, in 1997. Self-completed postal questionnaires issued in 1997, 2002, and 2005 were used to collect information on demographics, medication, and health status. Cross-sectional comparisons were made between data from 1997, 2002, and 2005. Results: Between 1997 and 2005, the proportion of patients treated with any disease-modifying anti-rheumatic drug (DMARD) including biologics increased substantially (from 52% to 87%), as well as the proportion treated with methotrexate (from 23% to 52%) and biologics (almost exclusively tumour necrosis factor inhibitors) (from 0% to 20%). Twelve per cent of RA patients received biologics 5... (More)
- Methods: A continuously updated population-based RA register was established in the city of Malmo, southern Sweden, in 1997. Self-completed postal questionnaires issued in 1997, 2002, and 2005 were used to collect information on demographics, medication, and health status. Cross-sectional comparisons were made between data from 1997, 2002, and 2005. Results: Between 1997 and 2005, the proportion of patients treated with any disease-modifying anti-rheumatic drug (DMARD) including biologics increased substantially (from 52% to 87%), as well as the proportion treated with methotrexate (from 23% to 52%) and biologics (almost exclusively tumour necrosis factor inhibitors) (from 0% to 20%). Twelve per cent of RA patients received biologics 5 years from disease onset in 2005. In parallel with changes in treatment, mean Health Assessment Questionnaire (HAQ) scores (1.19 vs. 0.89) and all Short Form 36 (SF-36) subscales improved from 1997 to 2005 (non-overlapping confidence intervals). Conclusion: Between 1997 and 2005, there was a substantial increase in the use of DMARDs, which was accompanied by improved mean HAQ and SF-36 scores in cross-sectional comparisons. These results support the concept that more intensive treatment with DMARDs and biologics can have profound effects on the overall health status in RA patients at the population level. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1619013
- author
- Soderlin, M. K. ; Lindroth, Y. ; Turesson, Carl LU and Jacobsson, Lennart LU
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Scandinavian Journal of Rheumatology
- volume
- 39
- issue
- 3
- pages
- 206 - 211
- publisher
- Taylor & Francis
- external identifiers
-
- wos:000277223800004
- scopus:77951811893
- pmid:20001765
- ISSN
- 1502-7732
- DOI
- 10.3109/03009740903313621
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Rheumatology Research Unit (013243310), Emergency medicine/Medicine/Surgery (013240200)
- id
- 080ee3a5-cc31-461f-809b-0d59cc09a9df (old id 1619013)
- date added to LUP
- 2016-04-01 10:52:17
- date last changed
- 2022-04-28 02:13:26
@article{080ee3a5-cc31-461f-809b-0d59cc09a9df, abstract = {{Methods: A continuously updated population-based RA register was established in the city of Malmo, southern Sweden, in 1997. Self-completed postal questionnaires issued in 1997, 2002, and 2005 were used to collect information on demographics, medication, and health status. Cross-sectional comparisons were made between data from 1997, 2002, and 2005. Results: Between 1997 and 2005, the proportion of patients treated with any disease-modifying anti-rheumatic drug (DMARD) including biologics increased substantially (from 52% to 87%), as well as the proportion treated with methotrexate (from 23% to 52%) and biologics (almost exclusively tumour necrosis factor inhibitors) (from 0% to 20%). Twelve per cent of RA patients received biologics 5 years from disease onset in 2005. In parallel with changes in treatment, mean Health Assessment Questionnaire (HAQ) scores (1.19 vs. 0.89) and all Short Form 36 (SF-36) subscales improved from 1997 to 2005 (non-overlapping confidence intervals). Conclusion: Between 1997 and 2005, there was a substantial increase in the use of DMARDs, which was accompanied by improved mean HAQ and SF-36 scores in cross-sectional comparisons. These results support the concept that more intensive treatment with DMARDs and biologics can have profound effects on the overall health status in RA patients at the population level.}}, author = {{Soderlin, M. K. and Lindroth, Y. and Turesson, Carl and Jacobsson, Lennart}}, issn = {{1502-7732}}, language = {{eng}}, number = {{3}}, pages = {{206--211}}, publisher = {{Taylor & Francis}}, series = {{Scandinavian Journal of Rheumatology}}, title = {{A more active treatment has profound effects on the health status of rheumatoid arthritis (RA) patients: results from a population-based RA register in Malmö, Sweden, 1997–2005}}, url = {{http://dx.doi.org/10.3109/03009740903313621}}, doi = {{10.3109/03009740903313621}}, volume = {{39}}, year = {{2010}}, }